Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials
从利匹韦林 (RPV)、恩曲他滨 (FTC) 和富马酸替诺福韦二吡呋酯 (TDF) 或依非韦伦、FTC 和 TDF 转换为利匹韦林 (RPV)、恩曲他滨 (FTC) 和替诺福韦艾拉酚胺复方制剂：两项随机临床试验的 96 周结果
期刊:Hiv Medicine
影响因子:3.2
doi:10.1111/hiv.12664
Hagins, D; Orkin, C; Daar, E S; Mills, A; Brinson, C; DeJesus, E; Post, F A; Morales-Ramirez, J; Thompson, M; Osiyemi, O; Rashbaum, B; Stellbrink, H-J; Martorell, C; Liu, H; Liu, Y-P; Porter, D; Collins, S E; SenGupta, D; Das, M
